Scancell founder says the company is ready to commercialise novel medicines to counteract cancer. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksYGEN.L Regulatory News (YGEN)

  • There is currently no data for YGEN

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

AGM Statement

30 Oct 2007 10:02

ViaLogy PLC30 October 2007 30 October 2007 ViaLogy plc AGM statement At the Annual General Meeting of ViaLogy PLC (VIY), the AIM-quoted technologycompany that is a leading innovator of network-centric, real time signalprocessing platforms for sensor applications, to be held at 10am today, theChairman, Terry Bond, will make the following statement. "It has been a year since shareholders approved the acquisition of the remainderof ViaLogy's share capital and the change of name to ViaLogy plc. During theyear the company has achieved a number of significant technical and productmilestones and the transition from research and development-driven activities tothe commercialisation of the technology is well underway. Over the next year ViaLogy will roll-out several products, principally SPM,MicroSPM and MPEX, initially targeting the defence, oil & gas and enterprisemarkets. These applications are based on ViaLogy's proprietary,patent-protected Quantum Resonance Interferometry (QRI) signal processingtechnology that enables the detection and interpretation of very weak signalsfrom large amounts of information and background noise. Ultimately SPM providesa solution to the problem of sensor integration. SPM, Sensor Policy Manager, is an enterprise-grade software product for sensorprocessing and interoperability. Unlike other sensor management solutions thatwork only with sensors from a single vendor, ViaLogy SPM software automaticallydiscovers network-attached sensors from any vendor, fuses and normalises theirinputs for central monitoring, and invokes real-time actions based oncustomer-defined policies. The network-centric approach provides measurablebenefits for security, safety and surveillance. The technology can integrate upto thousands of sensors connected to wireless and wired networks without delaysor loss of coverage. One of the early adopters of the SPM technology was Cisco Systems, which hasimplemented the technology at its San Jose campus to support safety and securityoperations, enabling the automation of complex facility operations. ViaLogy hasalso negotiated contracts for further SPM installations in the US and Taiwan. MicroSPM, is a compact, hardware-based solutions for real-time video and sensordata processing. It is designed to automate and improve the speed andeffectiveness of security and surveillance activities, such as face recognitionin crowds; human, object and vehicle detection and counting; and license platereading, in particular under difficult environment conditions. Reducingreliance on multiple human operators for analysis and decision-making. MPEX (Multi Parallax Exploitation) Electronic Eye, is a major advancement incomputer vision and video surveillance technology. In development with BoeingPhantom Works, the electronic eye is capable of 360 degree video processing,based on bionic principles that mimic the optical movements of some insects andreptiles. Initial applications for this technology will be for the detection ofvery fast moving targets such as missile interceptors, deployment of fast movingground vehicles and airborne platforms like unmanned aerial vehicles. Beyond these products other opportunities exist for ViaLogy's technology asannounced during the year. A technical breakthrough to improve the stability andperformance of miniature vibratory gyroscopes, achieved in collaboration withNASA's Jet Propulsion Laboratory and Boeing, which has wider applications in theemerging Micro Electro-Mechanical Systems (MEMS) market; the development of thedual-beam Reverse Photo-Acoustic Spectrometer (REPAS) with the Oak RidgeNational Laboratory for the detection of chemical, biological, radiological,nuclear and explosive materials; and, selection by the US Department of Defenseto provide a command and control platform for joint experiments to support thenext generation Joint Force Protection Advanced Security (JFPASS). An investment is being made to establish a strong sales and marketing team inorder for the Company to be able to exploit the opportunities available to it bybuilding relationships with potential partners and identifying global saleschannels. As you can see it is an exciting time for ViaLogy and the Board is enthusiasticand confident about the progress the Company will make over the next year andbeyond." End For further information please contact: ViaLogyTerry Bond, Chairman +44 (0)1235 834734 or 07860 842756Seymour Pierce Mark Percy, Nominated Adviser +44 (0)20 7107 8000Redleaf CommunicationsEmma Kane / Samantha Robbins +44 (0)20 7822 0200 About ViaLogy: Network Centric Signal Processing. ViaLogy is a leading innovator of network-centric, real-time signal processingplatforms for sensor applications. ViaLogy is currently deploying and designingcomputational systems, powered by its patented technologies, for applications inlife sciences, public safety and security, surveillance, defence andgeoseismology. Vialogy focuses on market driven problems where automation,timeliness, quality and reliability of information processing are essential.ViaLogy's core competency incorporates rapidly and accurately detecting weaksignals buried in high noise background and clutter. This technology can beemployed to solve problems involving sensor integration and information overloadchallenges involving video, telephony and control sensors, as well as forenhancement of numerous signal processing applications. For more information,visit our website at www.vialogy.com. Except for statements of historical fact, the information presented hereinconstitutes forward-looking statements within the meaning of the PrivateSecurities Litigation Reform Act of 1995. Such forward-looking statementsinvolve known and unknown risks, uncertainties and other factors which may causethe actual results, performance or achievements of the company to be materiallydifferent from any future results, performance or achievements expressed orimplied. This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
7th Feb 20177:00 amRNSSouthern Europe Business Update
10th Jan 20173:33 pmRNSResult of General Meeting
10th Jan 20177:15 amRNSHardman Research: Yourgene improves growth
21st Dec 20164:00 pmRNSPosting of Circular
21st Dec 20167:00 amRNSHalf year results
21st Dec 20167:00 amRNSConditional Acquisition of Yourgene Bioscience
21st Nov 20167:00 amRNSPremaitha establishes first service lab in Asia
31st Oct 20167:00 amRNSPremaitha welcomes UK Govt. decision on NIPT
27th Oct 20164:10 pmRNSResult of AGM
27th Oct 20167:00 amRNSAGM Statement
21st Oct 20167:00 amRNSGrant of Options
3rd Oct 20167:15 amRNSHardman Research: Excellent first year for IONA®
30th Sep 20163:38 pmRNSNotice of AGM
30th Sep 20167:00 amRNSFinal Results
23rd Sep 201610:42 amRNSHolding(s) in Company
23rd Sep 20168:50 amRNSNotice of results & appointment of broker
23rd Sep 20168:50 amRNSInvestment agreement extension with Thermo Fisher
8th Sep 20169:08 amRNSDirectorate Change
6th Jul 20167:00 amRNSDirectorate Change
4th Jul 20167:00 amRNSProgress on anti-trust objections to litigation
22nd Jun 20167:00 amRNSAdoption of Financial Reporting Standard (FRS) 101
22nd Apr 201610:45 amRNSUpdate on competitor patent litigation
20th Apr 201611:14 amRNSHardman Research: IONA sales & litigation update
20th Apr 20167:00 amRNSPatent Litigation Rescheduled
18th Apr 20161:13 pmRNSHardman & Co Issues Research Report
18th Apr 20161:03 pmRNSHardman & Co Issues Research Report
14th Apr 20167:00 amRNSHolding(s) in Company
13th Apr 20169:52 amRNSHolding(s) in Company
13th Apr 20167:00 amRNSHoldings in Company, Director's Shareholding
11th Apr 20167:00 amRNSTrading Update
29th Mar 20167:00 amRNSPremaitha announces tenth customer laboratory
21st Mar 20167:00 amRNSDistribution Agreements in the Middle East
9th Mar 20165:21 pmRNSHolding in Company, Directors' Dealing Replacement
9th Mar 20163:33 pmRNSHolding in Company, Directors' Dealings
9th Mar 20167:00 amRNSDistribution Agreement with GeNext - Russia
7th Mar 20167:00 amRNSAppointment of Joint Broker
3rd Feb 20167:00 amRNSPremaitha partners with Visional Medical in India
2nd Feb 20167:00 amRNSPremaitha partners with Leeds Hospitals NHS Trust
28th Jan 20167:00 amRNSHardman & Co Research Report: IONA®-Up and running
27th Jan 20167:00 amRNSTwo new customers signed for clinical lab service
26th Jan 20162:29 pmRNSUpdate on UK Litigation Timing
15th Jan 20167:00 amRNSPremaitha welcomes NSC recommendation on NIPT
8th Jan 201612:40 pmRNSUpdate on competitor patent litigation
18th Dec 20157:00 amRNSDirector/PDMR Shareholding
16th Dec 20155:53 pmRNSHolding(s) in Company
15th Dec 20157:00 amRNSHardman Issues Research Report
14th Dec 20157:00 amRNSInvestment Agreement with Thermo Fisher Scientific
14th Dec 20157:00 amRNSHalf Yearly Report
11th Dec 20157:00 amRNSNotice of Half Year Results
2nd Dec 20157:00 amRNSFirst IONA® testing service in France at LaboSud

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.